Abstract
Neuropathic pain (NP) remains a significant clinical challenge, as conventional pharmacological therapies often provide limited relief and are frequently associated with intolerable side effects. While non-invasive neuromodulation techniques like repetitive transcranial magnetic stimulation (rTMS) have shown analgesic potential, their efficacy is often restricted by an inability to stimulate deeper brain regions. Low-intensity transcranial focused ultrasound stimulation (TUS) is an emerging technology that allows for the precise, non-invasive targeting of deep brain structures. This paper outlines the protocol for the TUS-P-02 study, a randomised, participant-blinded, placebo-controlled trial designed to evaluate the long-term therapeutic efficacy and safety of repeated TUS sessions in patients with chronic NP.
Introduction
Neuropathic pain, caused by a lesion or disease of the somatosensory nervous system, often leads to a significant decrease in quality of life. Current treatments are frequently inadequate. While high-frequency rTMS over the primary motor cortex (M1) is a recognized intervention, its magnetic fields cannot effectively reach deeper targets, such as the posterior superior insula (PSI) or the motor cortex regions associated with lower-limb pain.
Focused ultrasound (TUS) offers a unique solution by utilizing acoustic energy that can be focused through the skull onto specific deep-tissue targets with millimetre precision. This protocol describes the first clinical trial to investigate whether repeated TUS sessions can induce sustained "offline" analgesic effects in patients with NP.
Methods and Study Design
The TUS-P-02 study is a three-arm, parallel-group, participant-blinded pilot trial. A total of 39 participants with chronic NP (duration ≥ 3 months; pain intensity ≥ 4 on the Numerical Rating Scale) will be enrolled and randomly allocated to one of three groups:
- TUS targeting the Primary Motor Cortex (M1): A traditional neuromodulation target for pain.
- TUS targeting the Posterior Superior Insula (PSI): A deep-brain hub critical for pain perception and processing.
- Sham Stimulation: The device is positioned identically, but no ultrasound energy is delivered.
Technical Intervention
The study utilizes the NeuroFUS system, employing a four-element annular array transducer. To ensure precision, the Brainsight neuro-navigation system is used in conjunction with individual 3D-MRI scans for each participant.
Stimulation parameters are set at a frequency of 500 kHz with a 10% duty cycle (10 ms pulses at 10 Hz) for a total duration of 580 seconds per session. To adjust for individual skull thickness and target depth (typically 43–54 mm), specialized ultrasound gel pads of varying thicknesses are used. Participants undergo one session per week for a total of eight weeks to evaluate the cumulative effects of the treatment.
Outcome Measures
The primary outcome is the change in weekly average pain intensity scores, as recorded by participants in a daily pain diary using the Numerical Rating Scale (NRS).
Secondary outcomes include:
- Pain Quality: Assessed via the Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2).
- Psychological Impact: Measured using the Hospital Anxiety and Depression Scale (HADS).
- Sensory Thresholds: Quantitative Sensory Testing (QST) to evaluate changes in thermal and vibration sensitivity.
- Cortical Excitability: Motor cortical excitability is measured via TMS to provide physiological evidence of neural modulation.
- Safety: Continuous monitoring for adverse events, adhering to the ITRUSST safety consensus (Mechanical Index of 1.32 and thermal dose below 0.25 CEM43).
Discussion and Key Insights
This trial addresses a critical gap in non-invasive brain stimulation: the "depth problem." By targeting the posterior superior insula, the study explores whether modulating deep pain-processing hubs can provide superior relief compared to superficial cortical stimulation. Furthermore, the use of TUS may overcome the anatomical hurdles that have previously made lower-limb neuropathic pain difficult to treat with rTMS.
As a pilot study, the sample size of 39 participants is powered to detect significant differences based on prior rTMS efficacy data. However, the study faces limitations, including the inability to blind the operators due to the technical requirements of the navigation system, and the inherent challenges of identifying the optimal "dose" for a relatively new technology.
Conclusion
The TUS-P-02 study represents a significant step forward in the search for non-surgical, non-pharmacological treatments for chronic pain. If TUS is shown to be safe and effective over an eight-week period, it could establish a new therapeutic category for patients who have exhausted conventional treatment options. Findings will be disseminated through peer-reviewed publications and scientific presentations upon the trial's completion.
Summary updated